$0.91
0.74% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US23283X2062
Symbol
CTSO

CytoSorbents Corporation Stock price

$0.91
-0.04 3.95% 1M
-0.18 16.85% 6M
-0.00 0.41% YTD
-0.16 15.30% 1Y
-1.16 56.22% 3Y
-7.61 89.36% 5Y
-5.39 85.61% 10Y
-75.34 98.81% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.01 0.74%

Key metrics

Basic
Market capitalization
$56.9m
Enterprise Value
$61.1m
Net debt
$4.2m
Cash
$10.2m
Shares outstanding
62.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.7 | 1.4
EV/Sales
1.8 | 1.5
EV/FCF
negative
P/B
4.9
Financial Health
Equity Ratio
23.5%
Return on Equity
-186.5%
ROCE
-41.8%
ROIC
-
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$34.3m | $39.8m
EBITDA
$-14.2m | $-12.3m
EBIT
$-15.9m | $-12.2m
Net Income
$-9.8m | $-8.3m
Free Cash Flow
$-10.4m
Growth (TTM | estimate)
Revenue
-7.8% | 11.9%
EBITDA
37.3% | 16.6%
EBIT
34.0% | 26.1%
Net Income
61.8% | 59.9%
Free Cash Flow
52.6%
Margin (TTM | estimate)
Gross
73.2%
EBITDA
-41.3% | -30.8%
EBIT
-46.5%
Net
-28.5% | -20.8%
Free Cash Flow
-30.3%
More
EPS
$-0.1
FCF per Share
$-0.2
Short interest
2.4%
Employees
149
Rev per Employee
$240.0k
Show more

Is CytoSorbents Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

CytoSorbents Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a CytoSorbents Corporation forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a CytoSorbents Corporation forecast:

Buy
75%
Hold
25%

Financial data from CytoSorbents Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
34 34
8% 8%
100%
- Direct Costs 9.18 9.18
30% 30%
27%
25 25
5% 5%
73%
- Selling and Administrative Expenses 35 35
5% 5%
102%
- Research and Development Expense 6.07 6.07
48% 48%
18%
-14 -14
37% 37%
-41%
- Depreciation and Amortization 1.79 1.79
12% 12%
5%
EBIT (Operating Income) EBIT -16 -16
34% 34%
-47%
Net Profit -9.75 -9.75
62% 62%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about CytoSorbents Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytoSorbents Corporation Stock News

Neutral
PRNewsWire
6 days ago
FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization PRINCETON, N.J. , Aug. 20, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, updates the regu...
Neutral
Seeking Alpha
18 days ago
Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Peter J. Mariani - Chief Financial Officer Phillip P.
Neutral
PRNewsWire
19 days ago
PRINCETON, N.J. , Aug. 7, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2025, and recent business highlights.
More CytoSorbents Corporation News

Company Profile

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.

Head office United States
CEO Phillip Chan
Employees 149
Founded 2002
Website cytosorbents.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today